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Abstract
OBJECTIVE: To systematically evaluate the curative
clinical efficacy and safety of sinomenine (SIN) in
treatment of rheumatoid arthritis (RA) in compari-
son to methotrexate (MTX).
METHODS:We searched the China National Knowl-
edge Infrastructure Database, Chinese Biomedical
Literature Database, China Science and Technology
Journal Database, Wanfang Database, Pubmed and
Cochrane Library electronically up to August 31,
2015, without language limitation. Only random-
ized controlled trials (RCTs) were included. Software
Review Manager 5.3 was used for Meta-analysis.
RESULTS: A total of 16 eligible studies within 1500
RA patients were included. The meta-analysis indi-
cated that on basis of MTX, SIN was more effective
in total effective rate (P < 0.000 01). Besides, SIN
alone versus MTX also showed advantages in RA
therapy (P = 0.04) Taken together, adverse events
occurred less frequently in combination of SIN and
MTX than MTX alone (P < 0.0001), especially in di-
gestive system (P < 0.000 01),while occurred more
in dermato mucosal system with SIN treatment ver-
sus MTX (P = 0.02), and were similar for both reme-
dies in nervous system (P = 0.12) and hematologi-
cal system (P = 0.25).
CONCLUTION: Compared to MTX, SIN had better
clinical efficacy and relatively fewer adverse events
in treatment of RA, especially when it was used to-
gether with MTX. Due to the poor methodological
quality, well-designed, multiple-center RCTs are
still required to further confirm the findings.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Rheumatoid arthritis (RA) is a progressive, destructive
inflammatory disease afflicting around 0.5%-2% of the
human population, especially females.1 The domestic
prevalence of RA is about 0.2% -0.4%.2 RA is charac-
terized by synovial inflammation leading to cartilage
and bone damage that is largely irreversible.3,4 It usually
starts as an insidious symmetrical polyarthritis, often
with non-specific symptoms such as malaise and fa-
tigue.5 50%-90% patients with erosive disease first
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develop their erosions > 2 years from disease onset.6
Although the exact cause of RA remains unknown, the
"Bermuda triangle" of genetics, environment and auto-
immunity is involved in the pathogenesis of RA.7 Meth-
otrexate (MTX) is a disease modifying anti-rheumatic
drug (DMARD) used as a first line agent for treating
RA for its proven efficacy, relative safety, and cost-effec-
tiveness.8,9 However, MTX is known to cause bone loss
and promote osteoclast formation, which is far from
ideal to prevent bone destruction in RA patients.10,11
Sinomenine (SIN) is a pure alkaloid extracted from
Chinese medicinal plant Qingfengteng (Caulis Sinome-
nii).12 Qingfengteng (Caulis Sinomenii) is recorded ini-
tially in Ben Cao Tu Jing of the Song Dynasty, has
functions such as dispelling the pathogen of wind and
dampness, dredging the channels and collaterals and re-
lieving pain.13,14 Studies have demonstrated that SIN
possesses potent anti-inflammatory, analgesic, and im-
munoinhibitory pharmacological effects, which pro-
vide the basis for RA treatment.15
Natural plant products offer a promising resource for
potential anti-arthritic agents, comprising one of the
most popular complementary and alternative medicine
(CAM) for inflammatory and immune disorders.3,16
Over the years, increasing proportion of patients with
RA are resorting to CAM for their health needs. The
prevalence of CAM usage by RA patients is anywhere
between 28% to 90%.17 In parallel, increasingly studies
have shown that SIN used alone or as adjuvant agent
combined with MTX had synergistic effects in inhibit-
ing RA response.18,19
In this study, in comparison to MTX, we aimed to eval-
uate the clinical efficacy and safety of SIN in RA
treatment.
METHODS
Literature retrieval and search strategies
Two reviewers searched the randomized controlled tri-
als (RCTs) conducted for SIN in treating RA from da-
tabase of China National Knowledge Infrastructure Da-
tabase (CNKI), Chinese Biomedical Literature Data-
base (CBM), China Science and Technology Journal
Database (VIP), Wanfang Database, Pubmed and Co-
chrane Library. The search included articles published
and updated up to August 31, 2015. Meanwhile, man-
ual searches for gray literatures of conference compila-
tions supplemented electronic searches were pre-
formed, while no documents were provided. Full de-
tails on the search terms were described as follows:
For Pubmed and Cochrane Library:
#1 Sinomenine [mh] OR Sinomenium [mh] OR
Zheng Qing Feng Tong Ning [mh] OR Zhengqing
Fengtongning tablets [mh]
#2 rheumatoid arthritis [mh] OR RA [mh]
#3 randomized controlled trials [pt] OR controlled
clinical trial [pt] OR randomized [tiab]
#1 AND #2 AND #3
For CNKI and other Chinese databases:
1# Qing Teng Jian [mh] OR Zheng Qing Feng Tong
Ning [mh]
2# Lei Feng Shi Guan Jie Yan [mh] OR Joint Pain [mh]
#1 AND #2
Inclusion criteria
(a) Types of studies. Trials must be a randomized, con-
trolled design, regardless of blinding or allocation con-
cealment. Quasi-RCTs were also taken into consider-
ation. Restrictions on language, status or publication
date were not set.
(b) Types of participants. According with specific clini-
cal diagnosis of RA, any participants of selected cases
were included whether mentioned patients were in ac-
tive phase or not. The diagnostic criteria for RA in the
trials accorded with the American Rheumatism Associa-
tion 1987 revised criteria for the classification of RA.20
(c) Types of interventions. Only trials of SIN prepara-
tions using alone or plus MTX versus MTX were con-
sidered Basic treatment may include non-steroidal an-
ti-inflammatory drug (NSAIDs) such as meloxicam,
but shouldn't include any other DMARDs or gluco-
corticoids.
(d) Types of outcome measures. The primary outcome
was the clinical efficacy, the secondary outcomes in-
cluded morning stiffness time, total clinical effective
rate in 4 weeks treatment, swollen joint count (SJC),
grip strength, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), blood platelet (PLT), disease
activity score for rheumatoid arthritis in 28 joints
(DAS28), health assessment questionnaire(HAQ)
score, and other outcome (anti-CCP).
Exclusion criteria
Studies were not considered if they met any of the fol-
lowing criteria. (a) Unpublished or repeated literature;
(b) non-RCTs, and clinical trials including experience
summary, case report, traditional reviews and animal
experiments; (c) studies not using SIN as the main
means of intervention; diagnosis complicated with
pregnancy, stroke, or other serious organic diseases
such as heart, liver, kidney and hematopoietic dysfunc-
tion; (d) cases with patients of severe drug allergic med-
ical history; (e) patients with other rheumatic diseases
at the same time.
Data extraction and quality assessment
The titles and abstracts of potentially relevant referenc-
es were identified through the literature search and re-
viewed independently by 2 reviewers (Liu Weiwei and
Wei Gang) according to predefined criteria and the Co-
chrane risk of bias tool.21 Any inconsistencies were re-
solved by discussion (95% level of agreement) or fur-
ther evaluated by consensus with another investigator
(Wang Yue). We assessed the methodological quality of
the included trials strictly according to the Cochrane
risk of bias tool. For each item, the judgment was giv-
en as "high risk", "unclear risk", or "low risk".
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Statistical analyses
Revman (version 5.3, the Nordic Cochrane Centre, Co-
chrane Collaboration, Copenhagen)22 and Stata 12.0
was used for data analysis. Outcomes were pooled us-
ing mean differences (MDs) for continuous variables,
and pooled risk ratio (RR) was used for dichotomous
variables, both with a 95% confidence interval (95%
CI). Heterogeneity was tested using Chi-square (χ²)
test and I 2 statistic. When heterogeneity was defined as
P < 0.05, I 2 > 50% among primary studies, it revealed
significant heterogeneity, random effects model was to
be used. Otherwise, if P > 0.05, I 2 < 50% fixed effects
model was to be applied. To maximize the similarities
among trials that would be combined, data was further
stratified possibly into subgroups based on consider-
ation of clinical factors, such as different types of inter-
ventions. Funnel plot analysis and Harbord's modified
test23 was done to determine publication bias. P < 0.05
was considered statistically significant.
RESULTS
Characteristics of included studies
In this review, the initial search yielded 775 articles,
CNKI (n = 357), CBM (n = 44), VIP (n = 106), Wan-
fang Data (n = 227), Pubmed (n = 39) and Co-
chrane Library (n = 2), of which 431 were excluded
owing to duplicated publication (n = 186) and irrele-
vant studies (n = 245). Following the evaluation of
the full text, 328 articles not meeting the inclusion
criteria were excluded, including non-RCTs (n = 14),
combining other Chinese medicine or traditional Chi-
nese in test group (n = 314). Finally, a total of 16
RCTs24-39 were available, all published in Chinese Jour-
nal Literature Databases from 2005 to 2015. The
screening process is summarized in a flow diagram (Fig-
ure 1).
Literature analysis
The characteristics of the 16 RCTs24-39 are summarized
in Table 1, containing a total of 1500 patients, each
ranging from 40 to 186 patients. The experimental
group consisted of 787 patients, while the control
group contained 713 patients. All the studies included
more females (67.1%) than males. The average age of
the patients was approximately 44.1 years. The disease
courses of RA were from 0.16 to 24 years. The dosage
of SIN was administered orally from 60 mg qd to
CNKI
(n = 357)
CBM
(n = 44)
VIP
(n = 106)
Wanfang
(n = 227)
Pubmed
(n = 39)
Cochrane
(n = 2)
Total
(n = 775)
Excluded
(n = 431)
Duplicated
(n = 186)
Irrelevant, animal
study, reviews
(n = 245)
Full-test articles
assessed for eligibility
(n = 344)
Excluded
(n = 328)
Non-RCTs
(n = 14)
Combining SIN injection,
other Chinese medicine,
acupuncture and massage
therapy in test group (n = 314)
Articles included in
quantitative synthesis
(Meta-analysis)
(n = 16)
Figure 1 Flow chart of literature search
CNKI: China National Knowledge Infrastructure Database; CBM: Chinese Biomedical Literature Database; VIP: Chinese Scientific
Journals Database; RCTs: randomized controlled trials.
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120 mg bid over 8 weeks. For the experimental group,
except 4 studies24,29,34,39 taking SIN alone, the rest of the
studies25-28,30-33,35-38 were treated plus MTX versus MTX
treatment alone, 5 trials27,30-32,35 adopted basic therapy,
one35 used folic acid to ameliorate side effects, 4 trials27,
30-32 used meloxicam during treatment, including one30
also added folic acid. The dosages and treatment cours-
es were not limited. 12 trials25,27-36,39 used the American
Rheumatism Association 1987 revised criteria for the
classification of RA (ARA-1987), including one 39 add-
ed the double criteria of Grading standard.40 One trial26
used the American College of Rheumatology/Europe-
an League Against Rheumatoid collaborative initiative
2010 RA classification criteria (ACR/EULAR-2010).
For TCM diagnostic criteria, one trial24 reported Wang-
bi in criteria of diagnosis and therapeutic effect of sur-
gica1 diseases and syndromes in traditional Chinese
medicine (CDTESDSTCM), one trial36 applied with
wind-dampness and blood-stagnant blocking collater-
als syndrome according to Guidelines of Clinical Re-
search of New Drugs of TCM (GCRNDTCM), 2 tri-
als37,38 have not reported clear diagnostic criteria.
Methodological quality assessment
Study quality was evaluated by Cochrane risk of bias
tool. All the eligible trials were RCTs, including one
quasi-RCT.25 None of the studies reported whether
blinding was used, or described allocation conceal-
ment. Only 2 studies25,26 described specific methods of
generating the random sequence, one26 described as ran-
dom digits table, and the other25 represented as se-
quence of medical order, while the rest lacked a descrip-
tion. One study31 reported 1 drop-out during the dura-
tion of treatment. Interestingly, one study26 described
some clear secondary outcomes, while lacking data of
clinical efficacy, we considered it may had selective re-
porting (Figures 2, 3). In addition, none of the trials re-
ported a follow-up.
Clinical efficacy
Only 15 trials25,25,27-39 including 1410 patients took clini-
cal efficacy as outcome measure. Meta-analysis showed
little significant heterogeneity among the studies (P =
0.83 > 0.05, I 2 = 0% < 50%), RR = 1.13, 95% [1.08,
1.19]. Fixed effects model was taken into consider-
ation. The overall effect tests (P < 0.000 01) suggested
that test group combined with SIN had a more signifi-
cant effective rate in treating RA than that of MTX
(Figure 4).
Publication bias
The publication bias in 15 included articles24-39 was
identified by funnel shape and Harbord's modified
test. The reversed funnel-shape plot showed generally
symmetrical (Figure 5), and the result of Harbord's
modified test was not significant (t = 1.07, P = 0.302,
Figure 6), indicating there might be no publication bi-
as in those studies.
Subgroup analysis
Subgroup analysis was made on the clinical efficacy ac-
cording to SIN alone and SIN plus MTX therapy both
contrast to MTX group in RA therapy. 11 studies25-28,
30-33,35-38 used SIN plus MTX as experimental group,
while 4 studies24,29,34,39 took only SIN as test group. The
heterogeneity (P = 0.45 > 0.05, I 2 = 0% < 50%) indi-
cated that fixed effect model should be applied. The re-
sult revealed that groups with SIN alone also had high-
er effective rate than that of MTX (P = 0.04, Figure 7).
Sensitivity analysis
We removed the most35 and the least34 weighted of every
subgroup and replaced fixed effects model to random
effects model to confirm the stability of the 15 includ-
ed studies24-39 on clinical efficacy. After removing the
most weighted, the result was RR = 1.10, 95% CI
(1.06, 1.15) (Figure 8), and the result of removing the
least weighted was [RR = 1.11, 95%CI (1.07, 1.16),
Figure 9]. Compared with the former results RR =
1.13, [95% CI (1.08, 1.19), Figure 4], there was no
clear difference of RR values, which indicated low sen-
sitivity and sound stability of the study.
Improvement of total clinical effective rate in 4
weeks treatment
Two trials33,36 were mentioned onset time in 4 weeks
during trial period. There was significant heterogeneity
(P < 0.00001, I 2 = 95% > 50%), random effect model
was taken. The Meta-analysis showed that there
weren't significant difference between groups of SIN
plus MTX and MTX alone (P = 0.12, Figure 10).
Morning stiffness time
Among 12 studies24,26-30,32,34-39 there were 1162 patents
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and measurement bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Free of baseline imbalance
Free of early stopping bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 2 Risk of bias of the included studies
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with the description of morning stiffness time (min).
High obvious heterogeneity was found (P < 0.000 01,
I 2 = 91% > 25%), random effect model was applied.
The result showed the test group with SIN could de-
crease morning stiffness time better than that of MTX
(P < 0.000 01). Moreover, the subgroup analysis indi-
cated that SIN alone also had better efficacy in decreas-
ing morning stiffness time versus MTX (P = 0.008,
Figure 11).
Swollen joint count (SJC)
Nine studies24,27-29,31,34,36,37,39 reported improvement in
numbers of SJC. Heterogeneity test showed that stud-
ies had a considerable degree of heterogeneity (P =
0.0009 < 0.05, I 2 = 70% > 50%), so random model
was chosen, there were significantly difference (P =
0.008). In parallel, subgroup analysis showed that SIN
alone had better efficacy in improving SJC (P = 0.02),
while SIN plus MTX had no advantages (P = 0.23),
both taken MTX as the contrast standard (Figure 12).
Grip strength
6 trials27-29,32,36,39 took grip strength (kpa) as the outcome
measure. There was significant heterogeneity (P <
0.000 01, I ² = 86% > 50%),random effect model was
taken. The Meta-analysis showed that test group com-
bined with SIN was better than MTX alone in promot-
ing grip strength (P = 0.03). The subgroup analysis in-
dicated that there was significant difference in the
group of SIN plus MTX (P = 0.04), while no differ-
ence in SIN alone (P = 0.71), both with the compari-
son of MTX therapy (Figure 13).
Erythrocyte sedimentation rate (ESR)
12 trials26-33,35-37,39 reported improvement in ESR. Het-
erogeneity test showed that the including studies had a
considerable degree of heterogeneity (P < 0.000 01,
I 2 = 76% > 50%), so random model was chosen, the
result showed that there were significantly difference
(P < 0.000 01). The subgroup analysis showed that
SIN alone had no advantages in decreasing ESR (P =
0.41), while SIN plus MTX had better efficacy (P <
0.000 01, Figure 14).
C-reactive protein (CRP)
Exact 11 studies26-28,30-33,35-37,39 referred to the improve-
ment in decreasing CRP. Due to the heterogeneity (P <
0.000 01, I 2 = 88% > 50%), we chose a random mod-
el. The result revealed that SIN combined with MTX
had better efficacy in decreasing CRP than MTX alone
(P < 0.0001, Figure 15).
Anti cyclic citrullinated peptide (anti-CCP)
Anti-CCP testing presents early in RA process and has
proved to predict severe disease and irreversible dam-
age.41 Unfortunately only was one trial35 mentioned an-
ti-CCP, we didn't take it in meta-analysis. The result in
trial showed SIN plus MTX had better efficacy than
MTX alone in decreasing anti-CCP (P < 0.05).
Blood platelet (PLT)
Two trials32,37 took PLT as outcome measure. Due to
the heterogeneity (P = 0.26 > 0.05, I 2 = 21% < 50%),
we choose a fixed model. The overall effect test (P <
0.0001) indicated that the test group combined with
SIN had a significantly effective rate in decreasing PLT
than MTX alone (Figure 16).
Disease activity score for rheumatoid arthritis in 28
joints (DAS28)
There were 4 studies31,35,37,38 reported improvement in
the DAS28.Heterogeneity test showed that the includ-
ing studies had little heterogeneity (P = 0.85 > 0.05, I 2 =
0% < 25%), so fixed effects model was chosen, the re-
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sult showed that SIN with MTX had better efficacy in
decreasing DAS28 than MTX alone (P < 0.000 01,
Figure 17) .
The health assessment questionnaire (HAQ) score
Among 3 studies30,35,36 there were 386 patents. Heteroge-
neity was shown in the studies (P < 0.000 01, I 2 =
Figure 4 Meta-analysis of the total clinical effective rate of sinomenine vsmethotrexate in rheumatoid arthritis treatment
Study regression line
95% CI for intercept
4
2
0
-2
0.0 0.5 1.0 1.5 2.0 2.5 3.0
sqrt (V)
Z/
sqr
t(V
)
Figure 6 Harbord's modified test of clinical effective rate
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Figure 5 Funnel plot of the clinical effective rate
Figure 7 Meta-analysis for subgroups of sinomenine alone versus Sinomening plus methotrexate in clinical efficacy
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99% > 50%). The random effect model was used. The
result showed that there was no obvious difference be-
tween the two remedies in improvement of HAQ score
(P = 0.08, Figure 18).
Adverse events (ADEs)
12 studies26-33,35-37,39 including 1177 cases reported ad-
verse events (ADEs) during RA treatment, mainly in-
cluded digestive system including gastrointestinal up-
set (T/C: 23/46) and Serum alanine transaminase
(ALT) raising (T/C: 6/26), hematological system in-
cluding white blood cell (WBC) declining (T/C: 8/
16), dermato mucosal system including skin rash(T/
C: 26/8), and nervous system including dizziness (T/
C: 2/6) (Table 2). The heterogeneity was no signifi-
cant (P = 0.5 > 0.05, I 2 = 0% < 25%), so the fixed
model was applied. Taken together, ADEs occurred
less frequently with the combination use of SIN than
using MTX alone (P < 0.0001, Figure 19). Addition-
ally, we made detailed analysis for ADEs of different
systems, the results indicated that events occurred
less frequently in the digestive system26-29,33,35-37,39 (P <
0.000 01, Figure 20) during the combination use of
SIN treatment than during MTX therapy, but oc-
curred more in the dermato mucosal system26-29,31,33,35-37,39
with SIN treatment (P = 0.02, Figure 21) than
MTX therapy, while adverse events of the nervous
system28,29,31,36 (P = 0.25, Figure 22) and hematological
system26-29,31,36,37,39 (P = 0.12, Figure 23) were similar
for both treatments.
Figure 8 Sensitivity analysis of removing the most weighted
Figure 9 Sensitivity analysis of removing the least weighted
Figure 10 Meta-analysis of total clinical effective rate in 4 weeks treatment in groups combined with sinomenine vsmethotrexate
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DISCUSSION
This review aimed to ascertain whether SIN therapy is
efficacious for RA, especially when combined with
MTX treatment. It must be acknowledged, however,
that the methodological quality of the studies was gen-
Figure 12 Meta-analysis of swollen joint count in subgroups of sinomenine alone and sinomenine plus methotrexate vs metho-
trexate
Figure 11 Meta-analysis of morning stiffness time with the subgroups of sinomenine alone and sinomenine plus methotrexate vs
methotrexate
Figure 13 Meta-analysis of grip strength in subgroups of sinomenine alone and sinomenine plus methotrexate vs methotrex-
ate
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Figure 14 Meta-analysis of erythrocyte sedimentation rate in subgroups of sinomenine alone and sinomenine plus methotrexate
vsmethotrexate
Figure 16 Meta-analysis of blood platelet in sinomenine plus methotrexate vsmethotrexate
Figure 15 Meta-analysis of C-reactive protein in sinomenine plus methotrexate vsmethotrexate
Figure 18 Meta-analysis of health assessment questionnaire score in sinomenine plus methotrexate vsmethotrexate
Figure 17 Meta-analysis of disease activity score for rheumatoid arthritis in 28 joints in sinomenine plus methotrexate vsmetho-
trexate
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Figure 19 Meta-analysis of adverse events in the groups combined with sinomenine vsmethotrexate
Figure 20 Meta-analysis of digestive systematic adverse events in the groups combined with sinomenine vsmethotrexate
Study
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Treatment group (n)
DS
Unclear
Unclear
3
4
3
0
Unclear
0
0
2
Unclear
0
12
3
Unclear
2
RS
1
0
0
0
0
0
0
0
0
0
0
DMS
1
3
1
0
1
2
1
9
5
1
2
HS
2
1
1
0
0
0
0
0
3
0
1
NS
0
0
0
2
0
0
0
0
0
0
0
A/T
7/45
8/30
5/30
2/60
5/48
1/40
2/35
3/62
9/120
20/52
4/36
5/60
Control group (n)
DS
4
11
4
8
Unclear
1
0
5
4
20
4
11
RS
3
0
0
0
0
0
0
0
0
0
0
DMS
1
1
0
2
0
0
1
0
0
1
2
HS
1
3
2
2
1
0
0
0
4
1
2
NS
0
0
2
0
1
0
0
0
3
0
0
A/C
9/45
15/30
8/30
10/60
13/48
2/40
0/34
6/58
4/66
27/52
6/36
15/60
Table 2 Characteristics of 16 included studies on adverse events for rheumatoid arthritis
Notes: DS: digestive system; RS: respiratory system; DMS: dermato mucosal system; HS: hematological system; NS: nervous system; A:
number of adverse events; T: case number in treatment group; C: case number in control group.
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erally not high. Firstly, the cases in our included arti-
cles were from 40 to 186, which meant there were no
large-scale RCTs, the current evidence was insufficient
to make a routine recommendation of SIN for RA
treatment. Besides, we thoroughly searched the English
database, while no eligible studies were found.
Secondly, among the 16 eligible trials24-39, only 4 trials24,
29,34,39 applied an A versus B design (totally different
make-up between the two groups), rest of the trials
used an A + B versus B design where patients are ran-
domized to receive a experimental treatment plus the
control treatment (Treatment Group) versus the con-
trol treatment (Control Group). This kind of design
tend to generate false positive results. Thus, stakehold-
ers should take critical thinking about the positive con-
clusions.
Thirdly, the duration of therapy in our included trials
was indeed too short to achieve conclusive results dur-
ing the chronic course of RA. Furthermore, none was
mentioned a follow-up period. The outcomes were on-
ly assessed at the end of the treatment (ranging from
8-24 weeks). Some long-term ADEs such as liver and
kidney functional damage would not be properly as-
sessed. Additionally, it is worth noting that all the trials
mentioned the number of ADEs, without distinguish-
ing whether its stands for patients' number of ADEs or
the number of ADE phenomenon itself, which may
lead to repeated counting and the final heterogeneity
in our Meta-analysis.
In conclusion, Meta-analysis can save cost and time dis-
posing the data of multiple independent trials to in-
crease sample size and to sharpen test performance. Be-
sides, it can provide evidence-based medical evidence
for clinicians in the areas of clinical practice.
This Meta-analysis from 15 aspects mentioned above
revealed that SIN therapy, especially combined with
MTX for RA had better clinical efficacy with less ad-
verse events than MTX therapy alone. In conclusion,
Figure 22 Meta-analysis of nervous systematic adverse events in the groups combined with sinomenine vsmethotrexate
Figure 21 Meta-analysis of dermato mucosal systematic adverse events in the groups combined with sinomenine vsmethotrexate
Figure 23 Meta-analysis of hematological systematic adverse events in the groups combined with sinomenine vsmethotrexate
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SIN may be a valuable way to treat RA in clinical prac-
tice, and the combination of SIN and MTX should be
taken more seriously clinically, although current evi-
dence needs to be further verified by more high-quality
trials.
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